Silence Therapeutics Plc - ADR
SLN - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$310.66M
Close$
$0.35
98.2% downside
Current Fair Value
98.2% downsideOvervalued by 98.2% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $310.66 Million |
|---|---|
| Enterprise Value | $238.49 Million |
| Earnings per Share | $-5.67 |
| Beta | 1.34 |
| Outstanding Shares | 15,745,529 |
Return
| Return on Equity | -101.36% |
|---|---|
| Return on Assets | -36.65% |
| Return on Invested Capital | -80.87% |
Valuation & Multiples
| P/E Ratio | -5.18 |
|---|---|
| PEG | 9.39 |
| Price to Sales | - |
| Price to Book Ratio | 9.87 |
| Enterprise Value to Revenue | 387.79 |
| Enterprise Value to EBIT | -3.15 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 5, 2026
EPS Estimate
$-0.11
Consensus analyst estimateRevenue Estimate
$113,400
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 4.69% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.08%▼ 141.15% |
|---|---|
| Total Invested | $139,632▼ 99.94% |
| Investors Holding | 4▼ 72.00% |
About Silence Therapeutics Plc
74 employees
CEO: David Solomon
Silence Therapeutics plc, a biotechnology firm headquartered in London, United Kingdom, is dedicated to the discovery and advancement of pioneering ribonucleic acid (RNA) therapeutics. Its research and development efforts span key areas ...